论文部分内容阅读
目前,对于何杰金氏病(HD)的临床行为已经有了较多的认识,因此治疗上取得了很大的进步。美国Stanford大学医院Ⅰ、Ⅱ期HD治疗后5年生存率已超过95％,Ⅲ、Ⅳ期亦可达75％。日本各期HD患者的相应数字为50～60％。非何杰金氏淋巴瘤(NHL)相对HD有更为恶性的临床经过,初诊时40～80％患者已属晚期,治疗则以化疗为主、某些局部区域放疗为辅,但疗效不理想。近15年来的临床观察表明,原发于结外(ENO)
At present, there has been more understanding of the clinical behavior of Hodgkin’s disease (HD), so great progress has been made in the treatment. The 5-year survival rate after stage I and II HD treatment at Stanford University Hospital in the United States has exceeded 95%, and it can reach 75% in stages III and IV. The corresponding figure for HD patients in Japan is 50 to 60%. Non-Hodgkin’s lymphoma (NHL) has a more malignant clinical course than HD. 40-80% of patients are already advanced at the time of initial diagnosis. Treatment is mainly based on chemotherapy, supplemented by local radiotherapy, but the effect is not satisfactory. . Clinical observations in the past 15 years have shown that primary out of the knot (ENO)